The New England journal of medicine
-
Comment Letter
Enteropathogens and chronic illness in returning travelers.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Pazopanib and sunitinib provided a progression-free survival benefit, as compared with placebo or interferon, in previous phase 3 studies involving patients with metastatic renal-cell carcinoma. This phase 3, randomized trial compared the efficacy and safety of pazopanib and sunitinib as first-line therapy. ⋯ Pazopanib and sunitinib have similar efficacy, but the safety and quality-of-life profiles favor pazopanib. (Funded by GlaxoSmithKline Pharmaceuticals; COMPARZ ClinicalTrials.gov number, NCT00720941.).
-
Randomized Controlled Trial Multicenter Study
Vedolizumab as induction and maintenance therapy for Crohn's disease.
The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown. ⋯ Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolizumab (rather than switching to placebo) were more likely to be in remission at week 52. Adverse events were more common with vedolizumab. (Funded by Millennium Pharmaceuticals; GEMINI 2 ClinicalTrials.gov number, NCT00783692.).